PE20091826A1 - Derivados de la 2-trifluorometilnicotinamida como agentes para aumentar el hdl-colesterol - Google Patents

Derivados de la 2-trifluorometilnicotinamida como agentes para aumentar el hdl-colesterol

Info

Publication number
PE20091826A1
PE20091826A1 PE2009000468A PE2009000468A PE20091826A1 PE 20091826 A1 PE20091826 A1 PE 20091826A1 PE 2009000468 A PE2009000468 A PE 2009000468A PE 2009000468 A PE2009000468 A PE 2009000468A PE 20091826 A1 PE20091826 A1 PE 20091826A1
Authority
PE
Peru
Prior art keywords
hydroxy
cholesterol
agents
nicotinamide
trifluoro
Prior art date
Application number
PE2009000468A
Other languages
English (en)
Inventor
Paul Hebeisen
Stephan Roever
Pius Waldmeier
Matthew Wright
Constantinos G Panousis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091826A1 publication Critical patent/PE20091826A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2-TRIFLUOROMETILNICOTINAMIDA DE FORMULA (I), DONDE R1 ES HIDROXIALQUILO INFERIOR, CICLOALQUILO SUSTITUIDO O NO POR HIDROXI, HIDROXIALQUILO INFERIOR, ENTRE OTROS; R2, R4 Y R8 SON CADA UNO H; R3 ES ALCOXIALQUILO INFERIOR, HALOALQUILO INFERIOR, HETEROALQUILO INFERIOR, ENTRE OTROS; R5, R6 Y R7 SON CADA UNO H, ALQUILO INFERIOR, HALOALCOXI INFERIOR, ENTRE OTROS. SON COMPUESTOS SELECCIONADOS: 5-(4-CLORO-FENIL)-N-(2-CICLOPROPIL-2-HIDROXI-PROPIL)-6-(2,2,2-TRIFLUORO-ETOXI)-2-TRIFLUOROMETIL-NICOTINAMIDA; N-(2-CICLOPROPIL-2-HIDROXI-PROPIL)-5-(3,4-DICLOROFENIL)-6-(2,2,2-TRIFLUORO-ETOXI)-2-TRIFLUOROMETIL-NICOTINAMIDA; 5-(3-CLORO-FENIL)-N-(CICLOPROPIL-2-HIDROXI-PROPIL)-6-(2,2,2-TRIFLUORO-ETOXI)-2-TRIFLUOROMETIL-NICOTINAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGENTES PARA AUMENTAR EL HDL-COLESTEROL SIENDO UTILES EN EL TRATAMIENTO DE HIPERCOLESTEROLEMIA, HIPERTRIGLICERIDEMIA, INFARTO DE MIOCARDIO, ENTRE OTROS
PE2009000468A 2008-03-31 2009-03-30 Derivados de la 2-trifluorometilnicotinamida como agentes para aumentar el hdl-colesterol PE20091826A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08153792 2008-03-31

Publications (1)

Publication Number Publication Date
PE20091826A1 true PE20091826A1 (es) 2009-11-25

Family

ID=40601113

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000468A PE20091826A1 (es) 2008-03-31 2009-03-30 Derivados de la 2-trifluorometilnicotinamida como agentes para aumentar el hdl-colesterol

Country Status (14)

Country Link
US (1) US7897621B2 (es)
EP (1) EP2262770B1 (es)
JP (1) JP5442711B2 (es)
KR (1) KR101249668B1 (es)
CN (1) CN101981009B (es)
AR (1) AR071096A1 (es)
AU (1) AU2009231375A1 (es)
CA (1) CA2717537A1 (es)
ES (1) ES2391371T3 (es)
IL (1) IL208021A0 (es)
MX (1) MX2010010000A (es)
PE (1) PE20091826A1 (es)
TW (1) TW200944504A (es)
WO (1) WO2009121740A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035324A1 (en) * 2009-09-21 2011-03-24 Vanderbilt University O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) * 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
KR101107896B1 (ko) * 2006-10-04 2012-01-25 에프. 호프만-라 로슈 아게 고 밀도 지단백질(ｈｄｌ)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체
DE602007006531D1 (de) * 2006-10-04 2010-06-24 Hoffmann La Roche Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren

Also Published As

Publication number Publication date
IL208021A0 (en) 2010-12-30
ES2391371T3 (es) 2012-11-23
KR101249668B1 (ko) 2013-04-01
CA2717537A1 (en) 2009-10-08
JP2011516444A (ja) 2011-05-26
US7897621B2 (en) 2011-03-01
TW200944504A (en) 2009-11-01
AR071096A1 (es) 2010-05-26
CN101981009B (zh) 2013-09-11
EP2262770B1 (en) 2012-08-01
KR20100117142A (ko) 2010-11-02
MX2010010000A (es) 2010-09-30
CN101981009A (zh) 2011-02-23
AU2009231375A1 (en) 2009-10-08
WO2009121740A1 (en) 2009-10-08
US20090247588A1 (en) 2009-10-01
JP5442711B2 (ja) 2014-03-12
EP2262770A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
PE20131377A1 (es) Triazina-oxadiazoles
PE20160843A1 (es) Pirrolidinonas herbicidas
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20141974A1 (es) Compuestos de heterociclilo
PE20080927A1 (es) Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk)
PE20070407A1 (es) Compuestos derivados de pirazina como antagonistas del receptor a2b de adenosina
PE20180177A1 (es) Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
PE20120691A1 (es) Derivados de n1-sulfonil-5-fluoropirimidinona
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20160751A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
PE20191142A1 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
PE20121058A1 (es) Compuestos que modulan el receptor de androgenos
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
AR096446A1 (es) Compuestos heterocíclicos como plaguicidas
PE20090888A1 (es) Compuestos heterociclicos como agentes moduladores del receptor acoplado a la proteina g gpr119
PE20150621A1 (es) Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20080890A1 (es) DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)

Legal Events

Date Code Title Description
FD Application declared void or lapsed